Mirum Pharmaceuticals Inc’s filing revealed that its Officer Radovich Peter acquired Company’s shares for reported $0.68 million on Mar 04 ’25. In the deal valued at $45.52 per share,14,850 shares were bought.
Then, Peetz Christopher sold 40,000 shares, generating $1,876,353 in total proceeds. Upon selling the shares at $46.91, the CHIEF EXECUTIVE OFFICER now owns 115,920 shares.
Before that, CHRISTOPHER PEETZ bought 40,000 shares. Mirum Pharmaceuticals Inc shares valued at $1,876,280 were divested by the Officer at a price of $46.91 per share.
Stifel initiated its Mirum Pharmaceuticals Inc [MIRM] rating to a Buy in a research note published on April 17, 2024; the price target was $48. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in mid December has reiterated a ‘”a Buy”‘ rating for it. Morgan Stanley started covering the stock on November 13, 2023. It rated MIRM as “an Overweight”.
Price Performance Review of MIRM
On Tuesday, Mirum Pharmaceuticals Inc [NASDAQ:MIRM] saw its stock fall -1.67% to $45.22. Over the last five days, the stock has lost -9.43%. Mirum Pharmaceuticals Inc shares have risen nearly 9.36% since the year began. Nevertheless, the stocks have risen 57.51% over the past one year. While a 52-week high of $54.23 was reached on 02/21/25, a 52-week low of $23.14 was recorded on 01/10/25. SMA at 50 days reached $46.80, while 200 days put it at $40.19.
Levels Of Support And Resistance For MIRM Stock
The 24-hour chart illustrates a support level at 44.70, which if violated will result in even more drops to 44.19. On the upside, there is a resistance level at 45.91. A further resistance level may holdings at 46.61. The Relative Strength Index (RSI) on the 14-day chart is 37.04, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.68, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 89.92%. Stochastics %K at 20.45% indicates the stock is a holding.
The most recent change occurred on October 24, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $50 price target.
